MELISSA ANDEL

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 5973/S 2323 - appropriations legislation covering the U.S. Food and Drug Administration; S 3295 and similar draft House legislation - appropriations legislation covering the Agency for Healthcare Research and Quality

HR 5973 and S 2323 - appropriations legislation covering the Food and Drug Administration

HR 5973 and S 2323 - appropriations legislation covering the Food and Drug Administration; S 3295 and similar draft House legislation - appropriations legislation covering the Agency for Healthcare Research and Quality

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 1893 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

Proposed changes to the Medicare Part D prescription drug benefit: modifying current Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse; legislation that would expand the current medication therapy management program in Part D (S 274/HR 891)

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.

Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.